AIIMS to start Phase I trial for testing the coronavirus vaccine.

AIIMS director Randeep Guleria on July 20, announced that the institute is going to start Phase 1 human trials for a coronavirus vaccine.

AIIMS director Randeep Guleria on July 20, announced that the institute is going to start Phase 1 human trials for a coronavirus vaccine.AIIMS director Dr. Randeep Guleria said that 1800 volunteers have registered to participate in the trial. Phase 2 of COVAXIN (name of the corona vaccine) will begin in AIIMS Delhi after the successful completion of Phase-1. The institute would get the results of Phase 1 within two to three months, and after injecting the vaccine, the institute would observe if any antibodies are developed in that person. Phase 1 of the trial would be conducted on healthy people aged between 18-55 years who have no co-morbidity. Randeep also said that the first phase of the trial is to ensure the safety of the vaccine and the dose range.

The vaccine has been developed by the Hyderabad-based pharmaceutical company in collaboration with the National Institute of Virology (NIV) and the Indian Council of Medical Research (ICMR). AIIMS, Delhi, was selected by the ICMR for conducting phase I and II trials. COVAXIN has been derived from a strain of the novel coronavirus isolated by the National Institute of Virology in Pune.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.